Patents
US 11266599 B2: Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
- Granted
- 2022-03-08
- Filed
- 2020-08-07 application 16988312
- Type
- Utility · 33 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
An embodiment of the present invention provides for a dry powder pharmaceutical composition suitable for dispersion in an aerosol for inhaled administration to a patient with cancer, the composition comprising: a cytidine analogue including salts, solvates, hydrates, and esters thereof; and a pharmaceutically acceptable excipient together forming the dry powder pharmaceutical composition suitable for dispersion in the aerosol for administration via inhalation to the patient with cancer. Another embodiment provides for a method of making the composition and a further embodiment provides for a method a treating a patient in need thereof with the composition.
Source: PVGPATDIS, file of 2026-04-10 (ipg220308.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Lovelace Biomedical Research Institute 1 patents | US company or organization | Albuquerque, NM | LOVELACE BIOMEDICAL RESEARCH INSTITUTE Federal lobbying client EXACT high confidence: identical full name and state LOVELACE BIOMEDICAL RESEARCH INSTITUTE Nonprofit EXACT high confidence: identical full name and state LOVELACE BIOMEDICAL RESEARCH INSTITUTE INC. State business registration FUZZY medium confidence: same name (legal endings aside) and state | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Steven A. Belinsky | Albuquerque, NM | 1 | Person page FUZZY high confidence | PVGPATDIS, file of 2026-04-10 |
| Philip J. Kuehl | Albuquerque, NM | 1 | PVGPATDIS, file of 2026-04-10 | |
| Aaron M. Badenoch | Bend, OR | 3 | PVGPATDIS, file of 2026-04-10 | |
| Michael Burke | Bend, OR | 1 | PVGPATDIS, file of 2026-04-10 | |
| Devon Brevard Dubose | Bend, OR | 3 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K9/0075 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P35/00 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2022-01-19 | Name change Change of name | LOVELACE RESPIRATORY RESEARCH INSTITUTE signed 2019-12-20 | LOVELACE BIOMEDICAL RESEARCH INSTITUTE ALBUQUERQUE, NM | 58770/222 | ECORSEXC, file of 2026-09-25 |
| 2022-01-19 | Assignment Assignment of assignor's interest | BEND RESEARCH, INC. signed 2019-08-16 | LOVELACE RESPIRATORY RESEARCH INSTITUTE ALBUQUERQUE, NM | 58694/596 | ECORSEXC, file of 2026-09-25 |
| 2022-01-18 | Assignment Assignment of assignor's interest | BADENOCH, AARON signed 2019-08-16 BURKE, MICHAEL signed 2019-08-16 DUBOSE, DEVON signed 2019-08-16 | BEND RESEARCH, INC. BEND, OR | 58682/968 | ECORSEXC, file of 2026-09-25 |
| 2022-01-17 | Assignment Assignment of assignor's interest | BELINSKY, STEVEN A. signed 2020-06-09 KUEHL, PHILIP J. signed 2020-06-09 | LOVELACE RESPIRATORY RESEARCH INSTITUTE ALBUQUERQUE, NM | 58670/379 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.